Bionano Genomics appoints Gülsen Kama as CFO effective September 11, 2023; Chris Stewart resigns

Bionano Genomics, Inc.

Kama's base salary set at $460,000/year with 55% target bonus; receives option for 106,000 shares vesting over 4 years.
Kama also gets a one-time $150,000 signing bonus contingent on one year of continuous employment.
Stewart's severance includes lump sums equal to six weeks base salary, additional six weeks upon strategic milestone, and six months base salary cash.
Stewart will consult at $500/hour through November 11, 2023, with equity vesting continuing during consulting period.
Kama previously served as CFO of Northern Data AG and East Region & Healthcare IT CFO at Quest Diagnostics.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Gülsen Kama

Chief Financial Officer

BNGO · Bionano Genomics, Inc.

Effective: 2023-09-11
Filed: August 14, 2023, 7:59 PM ET

On August 14, 2023, the Company announced the appointment of Gülsen Kama as Bionano Genomics, Inc.’s (the “Company”) Chief Financial Officer, effective as of September 11, 2023

Departed

Christopher Stewart

Chief Financial Officer

BNGO · Bionano Genomics, Inc.

Effective: 2023-09-11
Successor: Gülsen Kama
Filed: August 14, 2023, 7:59 PM ET

On August 11, 2023, Christopher Stewart resigned as Chief Financial Officer of the Company effective as of September 11, 2023

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Gülsen Kama was appointed as Chief Financial Officer at Bionano Genomics, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On August 14, 2023, the Company announced the appointment of Gülsen Kama as Bionano Genomics, Inc.’s (the “Company”) Chief Financial Officer, effective as of September 11, 2023

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Christopher Stewart resigned as Chief Financial Officer at Bionano Genomics, Inc..

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

On August 11, 2023, Christopher Stewart resigned as Chief Financial Officer of the Company effective as of September 11, 2023

View on SEC.gov

Bionano Genomics, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-23-039417

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.